OBJECTIVE: Spinal cord injury (SCI) affects a quarter million individuals in the United States, and there is currently no clinical treatment. Both fresh and acellular peripheral nerve grafts can induce spinal axon regeneration and support functional recovery in experimental injury models. Nonetheless, a scaffold that can be injected into a spinal contusion would be far less invasive to apply. We aimed to develop the first injectable acellular nerve graft for promoting repair after contusion SCI. APPROACH: We report a method to enzymatically solubilize optimized acellular (OA) nerve-a decellularized peripheral nerve graft developed in our laboratory and currently used clinically-to obtain an injectable solution that undergoes thermal gelation under physiological conditions. We quantified multiple physical and compositional properties of this novel material as well as tested its efficacy at acute and chronic time points following cervical contusion SCI. MAIN RESULTS: This injectable optimized acellular (iOA) nerve graft retains native chemical cues such as collagens and glycosaminoglycans. By varying hydrogel concentration, the rheological properties and compressive modulus of iOA were similar to that previous reported for rat central nervous tissue. iOA solution was compatible with rat Schwann cells in culture, and hydrogel injection into a rat cervical contusion model significantly reduced the ratio of M1:M2 macrophages after one week, favoring regenerative phenotypes (p < 0.05). Furthermore, while iOA treatment did not affect locomotor or respiratory recovery over an eight week period, the percentage of axonal coverage increased at the distal tissue interface (p < 0.05), suggesting enhanced axonal extension within this region. SIGNIFICANCE: Our data indicate that this novel injectable form of acellular nerve grafts is amenable for use after contusion SCI and may bolster a simultaneous therapy by acutely modulating the inflammatory milieu and supporting axonal growth.
OBJECTIVE:Spinal cord injury (SCI) affects a quarter million individuals in the United States, and there is currently no clinical treatment. Both fresh and acellular peripheral nerve grafts can induce spinal axon regeneration and support functional recovery in experimental injury models. Nonetheless, a scaffold that can be injected into a spinal contusion would be far less invasive to apply. We aimed to develop the first injectable acellular nerve graft for promoting repair after contusion SCI. APPROACH: We report a method to enzymatically solubilize optimized acellular (OA) nerve-a decellularized peripheral nerve graft developed in our laboratory and currently used clinically-to obtain an injectable solution that undergoes thermal gelation under physiological conditions. We quantified multiple physical and compositional properties of this novel material as well as tested its efficacy at acute and chronic time points following cervical contusion SCI. MAIN RESULTS: This injectable optimized acellular (iOA) nerve graft retains native chemical cues such as collagens and glycosaminoglycans. By varying hydrogel concentration, the rheological properties and compressive modulus of iOA were similar to that previous reported for rat central nervous tissue. iOA solution was compatible with rat Schwann cells in culture, and hydrogel injection into a rat cervical contusion model significantly reduced the ratio of M1:M2 macrophages after one week, favoring regenerative phenotypes (p < 0.05). Furthermore, while iOA treatment did not affect locomotor or respiratory recovery over an eight week period, the percentage of axonal coverage increased at the distal tissue interface (p < 0.05), suggesting enhanced axonal extension within this region. SIGNIFICANCE: Our data indicate that this novel injectable form of acellular nerve grafts is amenable for use after contusion SCI and may bolster a simultaneous therapy by acutely modulating the inflammatory milieu and supporting axonal growth.
Authors: Jessica A DeQuach; Joy E Lin; Cynthia Cam; Diane Hu; Michael A Salvatore; Farah Sheikh; Karen L Christman Journal: Eur Cell Mater Date: 2012-06-05 Impact factor: 3.942
Authors: Víctor Carriel; Miguel Alaminos; Ingrid Garzón; Antonio Campos; Maria Cornelissen Journal: Expert Rev Neurother Date: 2014-02-10 Impact factor: 4.618
Authors: Dmitry Tukmachev; Serhiy Forostyak; Zuzana Koci; Kristyna Zaviskova; Irena Vackova; Karel Vyborny; Ioanna Sandvig; Axel Sandvig; Christopher J Medberry; Stephen F Badylak; Eva Sykova; Sarka Kubinova Journal: Tissue Eng Part A Date: 2016-02 Impact factor: 3.845
Authors: Kun-Ze Lee; Brendan J Dougherty; Milapjit S Sandhu; Michael A Lane; Paul J Reier; David D Fuller Journal: Exp Neurol Date: 2013-08-13 Impact factor: 5.330
Authors: Susana R Cerqueira; Yee-Shuan Lee; Robert C Cornelison; Michaela W Mertz; Rebecca A Wachs; Christine E Schmidt; Mary Bartlett Bunge Journal: Biomaterials Date: 2018-05-28 Impact factor: 12.479
Authors: Deanna Bousalis; Michaela W McCrary; Natalie Vaughn; Nora Hlavac; Ashley Evering; Shruti Kolli; Young Hye Song; Cameron Morley; Thomas E Angelini; Christine E Schmidt Journal: J Biomed Mater Res A Date: 2021-09-29 Impact factor: 4.396
Authors: Vijay Kumar Kuna; Andre Lundgren; Luis Oliveros Anerillas; Peyman Kelk; Maria Brohlin; Mikael Wiberg; Paul J Kingham; Ludmila N Novikova; Gustav Andersson; Lev N Novikov Journal: Int J Mol Sci Date: 2022-08-06 Impact factor: 6.208
Authors: Adrian Dervan; Antonio Franchi; Francisco R Almeida-Gonzalez; Jennifer K Dowling; Ohemaa B Kwakyi; Claire E McCoy; Fergal J O'Brien; Alan Hibbitts Journal: Pharmaceutics Date: 2021-12-15 Impact factor: 6.321